Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21


19304 items
4:12 AM, Apr 24, 2018  |  BioCentury | Finance

Protein player

By modulating targets upstream of the ubiquitin proteasome system and inducing both stabilization and destabilization of target proteins, Third Rock Ventures believes newco Cedilla Therapeutics Inc. could have a broader reach than competing protein degradation...
6:28 PM, Apr 20, 2018  |  BioCentury | Product Development

Redrawing the lines

Word that Merck & Co. Inc.’s Keytruda pembrolizumab had “won” the first-line lung cancer showdown with Bristol-Myers Squibb Co. at AACR spread quickly on Monday, but there was little discussion among investors and in the...
5:44 PM, Apr 20, 2018  |  BioCentury | Finance

Takeda’s math problem

A hefty net debt load of $18.8 billion for Shire plc (LSE:SHP; NASDAQ:SHPG) means Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is having to pick its poison to reach a deal. The Japanese pharma is grappling with giving...
5:16 PM, Apr 20, 2018  |  BioCentury | Finance

Qiming’s cross-border connection

Qiming Venture Partners chose to focus its first ex-China fund on healthcare because the firm sees more interest in cross-border collaborations in life sciences than some of the other industries it invests in. Qiming unveiled...
5:01 PM, Apr 20, 2018  |  BioCentury | Finance

China’s early stage Panacea

Despite a recent wave of large funds investing in Chinese biotechs, new Chinese VC Panacea Venture believes a pair of funds totaling roughly $300 million is more than enough to pursue its early stage investing...
4:45 PM, Apr 20, 2018  |  BioCentury | Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
3:56 PM, Apr 20, 2018  |  BioCentury | Emerging Company Profile

Clear for Landos

Landos Biopharma Inc. is developing a first-in-class LANCL2 agonist designed to provide improved convenience, efficacy and safety over standard-of-care therapies for inflammatory bowel disease (IBD), including moderate to severe Crohn’s disease (CD) and ulcerative colitis...
3:04 PM, Apr 20, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in London; premarket on U.S. exchange; (B) Fiscal 4Q; (C) 12-month EPS. CompanyDatePre/post mkt1Q18 EPS est1Q17...
10:39 AM, Apr 20, 2018  |  BioCentury | Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
4:29 PM, Apr 13, 2018  |  BioCentury | Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...